Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
February 3rd, 2023
Bio-Gene Strikes Significant Deal with STK Bio-Ag Technologies
Read More
December 23rd, 2022
Top 6 Stock Picks for 2023
Read More
December 23rd, 2022
2023 Top Six Pick - Aroa Biosurgery: A Defensive Growth Stock for Investors
Read More
December 19th, 2022
Adalta Returns to IV Formulation for AD-214
Read More
December 19th, 2022
Dimerix Completes Recruitment of First Stage in Phase III Study
Read More
December 19th, 2022
Lecanemab Data Presented; Positive News for Cogstate
Read More
December 18th, 2022
Anteris Technologies to Progress Heart Valve to Early Feasibility Study
Read More
November 24th, 2022
Patrys AGM Highlights
Read More
November 4th, 2022
Imricor Medical Systems to Focus on Dedicated MRI Labs
Read More
November 4th, 2022
Pharmaxis Releases Initial Data in Myelofibrosis
Read More
November 4th, 2022
Aroa Biosurgery - Revenue Up 44%
Read More
November 4th, 2022
Cogstate Signs US$17.9 Million of Contracts in September Quarter
Read More
October 18th, 2022
Dimerix – Recruitment Accelerating in Phase III Study
Read More
October 18th, 2022
Antisense Therapeutics Revises Clinical Program in DMD
Read More
October 5th, 2022
Pharmaxis - Encouraging Early Data from Scar Removal Study
Read More
October 5th, 2022
Anteris Technologies - Aortic Valve Outperforms Surgical and TAVR Competitors
Read More
October 5th, 2022
Eisai Delivers Positive Phase III Alzheimer's Data
Read More
September 19th, 2022
Pharmaxis: Can PXS-6302 'Un-scar the Scar'?
Read More
September 19th, 2022
ResApp Health Sold to Pfizer for $180 Million
Read More
September 19th, 2022
Pharmaxis: Can PXS-6302 'Un-scar the Scar'?
Read More
Pages
1
2
3
4
5
6
7
8
9
